Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs-Reference-Cited by-同舟云学术

Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs

Published:2015-07-02 Issue:1 Volume:58 Page:43-58
ISSN:0323-3847
Container-title:Biometrical Journal
language:en
Short-container-title:Biom. J.

Author:

Skipka Guido¹,Wieseler Beate¹,Kaiser Thomas¹,Thomas Stefanie¹,Bender Ralf¹,Windeler Jürgen¹,Lange Stefan¹

Affiliation:

1. Institute for Quality and Efficiency in Health Care (IQWiG) 50670 Cologne Germany

Publisher

Wiley

Subject

Statistics, Probability and Uncertainty,General Medicine,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bimj.201300274

Reference24 articles.

1. Reflections on meta-analyses involving trials stopped early for benefit: Is there a problem and if so, what is it?

2. Gesetz zur Neuordnung des Arzneimittelmarktes in der gesetzlichen Krankenversicherung (Arzneimittelmarktneuordnungsgesetz—AMNOG);Bundesministerium für Gesundheit [BMG];Bundesgesetzblatt Teil 1,2010

3. Verordnung über die Nutzenbewertung von Arzneimitteln nach § 35a Absatz 1 SGB V für Erstattungsvereinbarungen nach § 130b SGB V (Arzneimittel‐Nutzenbewertungsverordnung—AM‐NutzenV);Bundesministerium für Gesundheit [BMG];Bundesgesetzblatt Teil 1,2010

4. The Relative Merits of Risk Ratios and Odds Ratios

5. Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: meta-epidemiological study

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comparison of Additional Benefit Assessment Methods for Time-to-Event Endpoints Using Hazard Ratio Point Estimates or Confidence Interval Limits by Means of a Simulation Study;Medical Decision Making;2024-05

2. Bayesian random‐effects meta‐analysis with empirical heterogeneity priors for application in health technology assessment with very few studies;Research Synthesis Methods;2023-12-28

3. Defining ‘therapeutic value’ of medicines: a scoping review;BMJ Open;2023-12

4. Prediction of therapeutic value of new drugs approved by health Canada from 2011−2020: A cross-sectional study;JRSM Open;2023-05

5. Barriers for the evaluation of advanced therapy medicines and their translation to clinical practice: Umbrella review;Health Policy;2022-12